OCC.AU Orthocell Ltd

Healthcare Biotechnology Australian Securities Exchange
0.5500 AUD
Close of Oct 30, 2026
0.4900 1.20
Market cap
AUD 150M
P/E
-
P/B
4.35x
ROE
-40.4%
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is OCC.AU undervalued?

Graham number

The Graham number of Orthocell Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orthocell Ltd fundamental analysis

7 of 21 checks passed

ROE 0/2

Low return on equity (-40.4%), below 10%.

ROA 1/1

Return on assets (-25.4%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-37.7%) is below the industry median (-5.3%).

Revenue Growth 2/2

Revenue grew 39.0% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (4.5%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Cash covers 3.1 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (4.4x) is below the industry median (4.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Orthocell Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orthocell Ltd

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and…

Full company profile